血清HBsAg动力学和与富马酸替诺福韦酯治疗HBeAg阴性慢性乙型

StephenW

J Viral Hepat. 2015 Jul 6. doi: 10.1111/jvh.12434. [Epub ahead of print]
Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.Papatheodoridis G1, Triantos C2, Hadziyannis E3, Zisimopoulos K2, Georgiou A1, Voulgaris T1, Vlachogiannakos I1, Nikolopoulou V2, Manolakopoulos S3.
Author information

• 1Department of Gastroenterology, Athens University Medical School, Laiko Hospital of Athens, Athens, Greece.
• 2Department of Gastroenterology, University Hospital of Patras, Patras, Greece.
• 32nd Department of Internal Medicine, Athens University Medical School, Hippokratio Hospital of Athens, Athens, Greece.
  

AbstractThe kinetics of serum HBsAg and interferon-inducible protein 10 (IP10) levels in patients with chronic hepatitis B infection treated with tenofovir are unclear. We evaluated the changes of HBsAg levels and the predictability of IP10 for HBsAg decline in 160 HBeAg-negative patients receiving tenofovir for ≥12 months. Serum samples taken before and at 6, 12, 24, 36 and 48 months after tenofovir were tested for HBsAg levels. In 104 patients, serum samples before tenofovir were tested for IP10 levels. Compared to before tenofovir, HBsAg levels decreased by a median of 0.08, 0.11, 0.24, 0.33 and 0.38 log10 IU/mL at 6, 12, 24, 36 and 48 months, respectively (P < 0.001). HBsAg kinetics did not differ between nucleos(t)ide analogue(s) naive and experienced patients. The 12-, 24-, 36- and 48-month cumulative rates of ≥0.5 log10 HBsAg decline were 8%, 16%, 24% and 41% and of HBsAg ≤100 IU/mL were 9%, 12%, 14% and 18%, respectively. The only factor associated with HBsAg ≤100 IU/mL was lower HBsAg levels before tenofovir (P < 0.001), while HBsAg decline ≥0.5 log10 was associated with higher IP10 levels (P = 0.002) and particularly with IP10 > 350 pg/mL (P < 0.001). In conclusion, tenofovir decreases serum HBsAg levels in both nucleos(t)ide analogue(s) naive and experienced patients with HBeAg-negative chronic hepatitis B infection. After 4 years of therapy, HBsAg ≤100 IU/mL can be achieved in approximately 20% of patients, particularly in those with low baseline HBsAg levels. HBsAg decline is slow (≥0.5 log10 in 40% of patients after 4 years) and is associated only with higher baseline serum IP10 levels.
© 2015 John Wiley & Sons Ltd.


KEYWORDS: HBsAg; hepatitis B; interferon-inducible protein 10; tenofovir

StephenW

Ĵ病毒Hepat。 2015年6月DOI：10.1111 / jvh.12434。 [打印EPUB的提前]
血清HBsAg动力学和与富马酸替诺福韦酯治疗HBeAg阴性慢性乙型肝炎患者干扰素诱导蛋白10血清实用性。
Papatheodoridis G1，Triantos C2，Hadziyann​​is E3，Zisimopoulos K2，乔治乌A1，Voulgaris T1，Vlachogiannakos I1，Nikolopoulou V2，Manolakopoulos S3。
作者信息

    消化内科教研室，雅典大学医学院，雅典Laiko医院，雅典，希腊。
    教研室消化，帕特雷，佩特雷，希腊的大学医院。
    内科，雅典大学医学院，雅典Hippokratio医院，雅典，希腊第32部。

抽象

血清HBsAg和干扰素诱导蛋白10动力学（IP10）慢性乙肝感染治疗的替诺福韦水平目前还不清楚。我们评估HBsAg水平的IP10的HBsAg的下降在接受泰诺福韦为≥12个月160 HBeAg阴性患者可预测性的变化和。拍摄前的血清样本，并在6，12，24，36和48个月替诺福韦后进行了测试HBsAg水平。 104例，替诺福韦前血清样品进行了测试IP10水平。相比的替诺福韦之前，HBsAg水平在6，12，24，36和48个月内，分别（P <0.001）减少了0.08，0.11，0.24，0.33和0.38日志10 IU / mL的中位数。 HBsAg的动力学没有核苷（酸）类似物IDE（S）天真和经验的患者之间的差异。的≥0.5日志10的HBsAg下降的12-，24-，36-和48个月的累积率分别为8％，16％，24％和41％的与HBsAg≤100IU /毫升的分别为9％，12％，14％和18％，分别为。与乙肝表面抗原≤100IU / mL的相关的唯一因素是低HBsAg水平替诺福韦前（P <0.001），而HBsAg的下降与更高级别为IP10（P = 0.002），特别是与相关IP10≥0.5日志10> 350皮克/毫升（ P <0.001）。总之，替诺福韦降低血清HBsAg水平在核苷（酸）类似物IDE（S）天真和经验丰富例HBeAg阴性慢性乙型肝炎病毒感染。经过4年的治疗，乙肝表面抗原≤100IU / mL的可在约20％患者来实现，特别是在那些具有低基线HBsAg水平。 HBsAg的下降是缓慢的（≥0.5日志10中40％的患者术后4年），并且只具有更高的基线血清IP10水平有关。

2015年©约翰·威利父子有限公司
关键词：

乙肝表面抗原;乙型肝炎;干扰素诱导蛋白10;替诺福韦

682256

IP10是注射干扰素激发产生的？

StephenW

回复 682256 的帖子

CXCL10（英语：C-X-C motif chemokine 10）是一小分子的细胞因子属于CXC趋化因子家族[1]，又被称作“干扰素伽玛诱导的10千道尔顿蛋白”（10 kDa interferon-gamma-induced protein，IP-10）[2] 。干扰素伽玛可以在多种细胞（如巨噬细胞[3] ，单核细胞[3] ，内皮细胞[4]和成纤维细胞）中诱导CXCL10的表达。CXCL10的功能包括对T细胞和单核细胞的细胞趋化作用[5][6]，促进T细胞黏附于内皮细胞[4]，抗肿瘤[7]，及新血管形成[4]。人类的CXCL10基因与CXCL9，CXCL11的基因相邻聚集在第四染色体上。CXCL10, CXCL9和CXCL11结合趋化因子受体CXCR3而起其细胞趋化作用[5][6]